// App-Quantinova.ai

: Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

Researchers

Presenter

  • Edoardo Pennesi

Principal Investigators

  • Kathleen B. Pelletier

  • Ying Chen

  • Alwin D.R. Huitema

  • Yilin Jiang

  • Anneke C.J. Ammerlaan

  • Barbara Sleight

  • Franco Locatelli

  • Inge M. van der Sluis

  • Claudia Rossig

  • Christiane Chen-Santel

  • Bella Bielorai

  • Arnaud Petit

  • Jan Stary

  • Lucie Sramkova

  • Cristina Diaz de Heredia Rubio

  • Susana Rives

  • Aengus O'Marcaigh

  • Carmelo Rizzari

  • Gernot Engstler

  • Karsten Nysom

  • Alba Rubio-San-Simón

  • Francisco J. Bautista Sirvent

  • Benedicte Bruno

  • Yives Bertrand

  • Benoit Brethon

  • Fanny Rialland

  • Genevieve Plat

  • Uta Dirksen

  • May Garrett

  • Christian M. Zwaan

Medical Centers

  • The Netherlands Cancer Institute, Amsterdam, Netherlands

  • Pediatric Hematology-Oncology Unit, University of Milano-Bicocca, MBBM Foundation, San Gerardo Hospital, Monza, Italy

  • University Medical Center Utrecht, Utrecht, Netherlands

  • Department of Pediatric Oncology and Hematology, Hospital Niño Jesús, Madrid, Spain

  • Division of Pediatric Hematology and Oncology, Hospital Universitario Vall d´Hebron, Barcelona, Spain

  • Division of Pediatric Hematology and Oncology, Sheba Medical Center, Ramat-Gan, Israel

  • Department of Pediatric Hematology and Immunology, Robert-Debré Hospital, AP-HP, University of Paris, Paris, France

  • Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark

  • St Anna Children's Hospital, Medical University of Vienna, Vienna, Austria

  • Pediatric Hematology, Hôpital Jeanne de Flandre, CHRU de Lille, Lille, France

  • Institute of Pediatric Hematology and Oncology, Civil Hospital of Lyon - Claude Bernard University, Lyon, France

  • Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands

  • Pediatrics III, West German Cancer Center, German Cancer Consortium (DKTK), Essen University Hospital, Essen, Germany

  • Service Onco-Hématologie Pédiatrique, Hôpital Mère-Enfant, Nantes University Hospital, Nantes, France

  • Department of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic

  • Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands

  • IRCCS Ospedale Pediatrico Bambino Gesú, Catholic University of the Sacred Heart, Rome, Italy

  • Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Deu de Barcelona, Barcelona, Spain

  • The Hospital for Sick Children, Dublin, IRL

  • Pediatric Hematology and Oncology Department, Trousseau Hospital, Hopital Armand Trousseau, APHP, Sorbonne Université, Paris, France

  • Rostock Medical Center, Rostock, Germany

  • Department of Pediatric Hematology and Oncology, University Children's Hospital Münster, Münster, Germany

  • Service d'Hématologie-Immunologie-Oncologie, Hôpital des Enfants - CHU Toulouse, Toulouse, France

Locations

  • Netherlands

  • France

  • Germany

  • United States

  • Italy

  • Denmark

  • Austria

  • Czech Republic

  • Spain

  • Israel

Companies

  • Pfizer Inc.

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Non-Hodgkin's Lymphoma

  • Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Lymphomas

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Inotuzumab ozogamicin

  • Rituximab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved